Rubella virus recombinant virus-like particle expression vector and its use
The rubella virus recombinant virus-like particle expression vector expresses rubella virus structural proteins in mammalian cells, forming virus-like particles, solving the problem of difficult antigen sensitivity and specificity in existing detection methods, and achieving more efficient rubella virus detection .
Patent Information
- Application Number
- CN202310293425.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-03-23
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2043-03-23
AI Technical Summary
In the existing rubella virus detection methods, the sensitivity and specificity of antigens are difficult to take into account, resulting in false positive and false negative problems, and it is impossible to effectively detect rubella virus infection.
Provide a rubella virus recombinant virus-like particle expression vector, which contains a nucleotide sequence encoding the Thereen subtype rubella virus capsid protein and envelope protein, and obtains the rubella virus recombinant protein through mammalian cells to form virus-like particles for Prepare kits and vaccines to improve the sensitivity and specificity of detection.
It achieves higher sensitivity and specificity of rubella virus detection, reduces false positives and false negatives, provides more specific and accurate detection raw materials, and is suitable for laboratory diagnosis and large-scale on-site investigation of rubella virus infection.
Smart Images

Figure CN116376977B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the medical field, and in particular to a rubella virus recombinant virus-like particle expression vector and a use thereof. Background Art
[0002] Rubella virus is the only member of the genus Rubellavirus in the family Togaviridae. Rubella virus (RV), which is spherical in shape, is the pathogen of rubella, and humans are its only host. Rubella is an acute respiratory infectious disease with fever, respiratory inflammation and rash as the main symptoms. Pregnant women, especially those in early pregnancy, infected with rubella virus can cause congenital rubella syndrome (CRS) in the fetus. Rubella and CRS occur all over the world, with a high infection rate in Asia. After pregnant women are infected with rubella virus, especially in the first 3-4 months of pregnancy, rubella virus can invade the placenta and transmit to the fetus, causing congenital rubella virus infection as high as 30-35%. In addition to stillbirth, miscarriage and premature birth, the fetus may also have one or more malformations, such as cardiovascular malformations, eye diseases, neurological deafness, microcephaly, intellectual disability, etc. The mortality rate of infants can reach 10-20% within 1 year after birth.
[0003] Rubella virus (RV) is divided into two branches (Clade 1 and Clade 2) on the genetic evolution tree. Currently, there are 13 genotypes in the two branches, 12 of which are official genotypes (1B, 1C, 1D, 1E, 1F, 1G, 1H, 1I, 1J, 2A, 2B, 2C), and one is a temporary genotype (1a). There are a total of 8 subtypes (BRDⅠ, BRDⅡ, Cendehill, M33, RN-UK86, Therien, TO-336, RA27 / 3).
[0004] At present, the diagnostic methods for rubella virus infection include virus isolation, serological diagnosis and molecular biological detection. However, due to the long virus isolation and culture cycle and high risk, molecular biological detection has high sample requirements and other defects.
[0005] Immunological methods are easy to operate and commonly used in clinical practice, making them suitable for laboratory diagnosis and large-scale field investigations of rubella virus infection. At present, the antigens used in most detection kits are inactivated natural rubella viruses or recombinantly expressed single or multiple protein fragments of rubella viruses. Although the sensitivity of inactivated natural rubella viruses is better than that of recombinant proteins, due to problems with the preparation process, the low purity of the antigens results in poor specificity, which causes false positives and reduces the specificity of the detection. The recombinantly expressed single or multiple protein fragments of rubella viruses have better specificity due to their large differences in spatial structure from natural viruses, but their sensitivity is worse than that of inactivated natural rubella viruses, and there are more false negatives, which reduces the specificity of the detection. In short, the performance of existing antigens on the market cannot take into account both sensitivity and specificity.
[0006] Therefore, there is an urgent need to develop a rubella virus antigen that takes both sensitivity and specificity into account. Summary of the invention
[0007] The present invention aims to solve one of the technical problems in the related art at least to a certain extent.
[0008] To this end, an object of the present invention is to provide an expression vector, the nucleotide sequence of which includes nucleotides encoding the capsid protein and envelope protein of the Therien subtype rubella virus, the capsid protein is protein C, and the envelope protein is protein E1 and protein E2.
[0009] The rubella virus recombinant protein expressed by the rubella virus recombinant virus-like particle expression vector provided by the present invention covers all structural proteins (C, E1, E2) of rubella virus, and the expressed recombinant protein exists in the form of virus-like particles. The preparation process is simple, the antigen purity is high, and the detection sensitivity and specificity are better than those of inactivated natural rubella virus and recombinantly expressed rubella virus single or multiple combination protein fragments, which can effectively avoid the above problems and provide more specific and accurate raw materials for the detection of rubella virus infection.
[0010] According to some embodiments of the present invention, the nucleotide sequence of the expression vector includes the sequence shown in SEQ ID NO.1.
[0011] According to some embodiments of the present invention, the expression vector is a mammalian cell expression vector.
[0012] According to some embodiments of the present invention, the expression vector is selected from any one of pCDNA3.1 plasmid, pCDNA3.4 plasmid, pBD plasmid, pCMV plasmid, pFLAG plasmid, and pEF1α plasmid.
[0013] According to some embodiments of the present invention, the expression vector is a pCDNA3.1 plasmid, wherein the neomycin resistance gene on the pCDNA3.1 plasmid is replaced by a glutamine synthetase gene.
[0014] According to some embodiments of the present invention, the nucleotide sequence of the expression vector is shown as SEQ ID NO.4.
[0015] Another aspect of the present invention provides a recombinant cell, wherein the recombinant cell comprises the above-mentioned expression vector.
[0016] According to some embodiments of the invention, the recombinant cell is a mammalian cell.
[0017] According to some embodiments of the present invention, the recombinant cell is selected from any one of M14, HeLa, HepG2, THP-1, MCF-7, CHO-S, and 293S cells.
[0018] According to some embodiments of the invention, the recombinant cell is a CHO-S cell.
[0019] Another aspect of the present invention provides a recombinant Rubella virus virus-like particle, wherein the recombinant Rubella virus virus-like particle is obtained by expressing the above-mentioned recombinant cell.
[0020] According to some embodiments of the present invention, the diameter of the Rubella virus recombinant virus-like particle is 100-150 nm.
[0021] According to some embodiments of the present invention, the Rubella virus recombinant virus-like particle does not contain genetic material of Rubella virus.
[0022] In another aspect, the present invention provides a method for preparing recombinant virus-like particles of rubella virus, comprising: transfecting the recombinant cells with the expression vector, culturing the recombinant cells, and expressing the recombinant virus-like particles of rubella virus.
[0023] In yet another aspect, the present invention provides a kit, which comprises at least one of the above-mentioned expression vector, recombinant cells, and recombinant virus-like particles of Rubella virus.
[0024] Another aspect of the present invention provides use of the above-mentioned expression vector, recombinant cell, and rubella virus recombinant virus-like particle in preparing a kit for detecting rubella virus.
[0025] According to some embodiments of the present invention, the kit is an enzyme immunoassay kit or a colloidal gold detection kit or a chemiluminescence detection kit.
[0026] In yet another aspect, the present invention provides a composition comprising at least one of the above-mentioned expression vector, recombinant cell, and recombinant virus-like particle of Rubella virus.
[0027] In yet another aspect, the present invention provides a vaccine comprising at least one of the above-mentioned expression vector, recombinant cell, and recombinant virus-like particle of rubella virus.
[0028] Another aspect of the present invention provides the use of the above-mentioned expression vector, recombinant cell, and rubella virus recombinant virus-like particle in the preparation of a drug, wherein the drug is used to prevent rubella virus-mediated related diseases.
[0029] Additional aspects and advantages of the present invention will be given in part in the following description and in part will be obvious from the following description, or will be learned through practice of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] The above and / or additional aspects and advantages of the present invention will become apparent and easily understood from the description of the embodiments in conjunction with the following drawings, in which:
[0031] Figure 1 The ability of 8 different subtypes of rubella viruses in Example 1 of the present invention to recognize specific IgG antibodies in different human sera is shown, wherein Negative represents human serum samples not infected with rubella virus, and Positive represents human serum samples infected with rubella virus;
[0032] Figure 2 The pCG3.1 plasmid map in Example 2 of the present invention is shown;
[0033] Figure 3 The plasmid map of the recombinant plasmid pCG3.1-Rubella (VLPs) in Example 3 of the present invention is shown;
[0034] Figure 4 The activity bar graph comparing the transient expression of Rubella virus recombinant virus-like particles by different mammalian cells in Example 4 of the present invention is shown;
[0035] Figure 5 A line graph showing the detection of cell density of the stable cell line of clone number 180H2 in Example 6 of the present invention;
[0036] Figure 6 A line graph showing the detection of cell survival rate of the stably transfected cell line of clone number 180H2 in Example 6 of the present invention;
[0037] Figure 7 The growth curves of 180H2 cells cultured in the optimal medium and CDCHO medium in Example 7 of the present invention are shown;
[0038] Figure 8 A bar graph showing the sensitivity and specificity of Rubella (VLPs) in detecting specific IgG and IgM antibodies in serum in Example 8 of the present invention. DETAILED DESCRIPTION
[0039] The embodiments of the present invention are described in detail below. The embodiments described below are exemplary and are only used to explain the present invention, and should not be understood as limiting the present invention.
[0040] It should be noted that the terms "first" and "second" are used for descriptive purposes only and should not be understood as indicating or implying relative importance or implicitly indicating the number of the indicated technical features. Therefore, the features defined as "first" and "second" may explicitly or implicitly include one or more of the features. Further, in the description of the present invention, unless otherwise specified, the meaning of "plurality" is two or more.
[0041] The endpoints and any values of the ranges disclosed in this article are not limited to the precise ranges or values, and these ranges or values should be understood to include values close to these ranges or values. For numerical ranges, the endpoint values of each range, the endpoint values of each range and the individual point values, and the individual point values can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed in this article.
[0042] In order to make the present invention more easily understood, certain technical and scientific terms are specifically defined below. Unless otherwise clearly defined elsewhere in this document, all other technical and scientific terms used herein have the meanings commonly understood by those skilled in the art to which the present invention belongs.
[0043] In this document, the terms “include” or “comprising” are open expressions, that is, including the contents specified in the present invention but not excluding other contents.
[0044] As used herein, the terms "optionally", "optional" or "optionally" generally mean that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.
[0045] In this article, the term "virus-like particles" (virus like particles, VLPs) is a hollow shell structure that does not contain viral nucleic acid. Many viral structural proteins have the ability to automatically assemble into VLPs, which are similar to natural viral particles in morphology and structure, and have strong immunogenicity and biological activity. Since VLPs do not contain viral genetic material, they are not infectious, and some of them have been successfully used in clinical practice as vaccines. VLPs structurally allow the insertion of exogenous genes or gene fragments to form chimeric VLPs and display exogenous antigens on their surfaces. In addition, most viral VLPs also have the ability to encapsulate nucleic acids or other small molecules.
[0046] In this article, the term "capsid protein" is a viral gene product that has virus-specific antigenicity and can stimulate the body to produce an antigenic viral immune response.
[0047] As used herein, the term "envelope protein" refers to proteins that constitute the viral envelope structure, including envelope glycoproteins and matrix proteins.
[0048] In the text, the term "neomycin resistance gene" is a gene encoding aminoglycoside phosphotransferase. It refers to a gene that is inserted when constructing an expression plasmid and is resistant to neomycin and can be used to screen expressive recombinant plasmids.
[0049] In this article, the term "glutamine synthetase" (Cricetulus, GS) is an enzyme that controls nitrogen metabolism. The amino acid glutamine is not only used by cells to synthesize proteins, but also to transport nitrogen. The growth of mammalian cells cannot be separated from glutamine. The endogenous glutamine synthetase activity of CHO cells is relatively low, and it is unable to express enough glutamine to maintain rapid cell growth. Exogenous glutamine must be added to the culture medium.
[0050] In this article, the term "methionine sulfoximine" (MSX), a GS inhibitor, can be used to inhibit endogenous GS activity. An expression vector containing a target gene and a GS gene marker is used to transfect host CHO cells, and MSX pressure screening is used to promote the amplification of the GS gene and the target protein gene. Only cells transfected with the additional GS gene can grow in a culture medium without L-glutamine, thereby screening and obtaining recombinant expression cell lines.
[0051] In this article, the term "antibody" is also referred to as immunoglobulin, which is a tetrameric glycoprotein. In naturally occurring immunoglobulins, each tetramer is composed of two pairs of identical polypeptide chains, each pair having a "light" (about 25kDa) and a "heavy" chain (about 50-70kDa). Each heavy chain has a variable domain (VH) at one end, followed by a number of constant domains. Each light chain has a variable domain (VL) at one end and a constant domain at the other end; the constant domain of the light chain is aligned with the first constant domain of the heavy chain, and the light chain variable domain is aligned with the variable domain of the heavy chain.
[0052] In this article, the term "immunogenicity" refers to the ability to cause an immune response, that is, the ability of an antigen to stimulate specific immune cells, causing them to activate, proliferate, and differentiate, and ultimately produce immune effector substances such as antibodies and sensitized lymphocytes. The immunogenicity of an antigen is first determined by its own chemical properties, but the immunogenicity of the same antigen to different species of animals or different individuals of the same species can vary greatly. Therefore, the immunogenicity of an antigen is determined by its chemical properties and host factors. Immunogenic substances are called immunogens.
[0053] In this article, the term "rubella virus-mediated diseases" includes any related diseases caused directly or indirectly by rubella virus, including arthritis, ear infections and encephalitis caused by rubella, and congenital rubella syndrome (growth retardation, cataracts, deafness, congenital heart defects and mental retardation) in infants born to pregnant women infected with rubella.
[0054] The technical difficulty of the present invention is that on the one hand, there are many genotypes of Rubella virus and the nucleotide sequence is quite different, which makes the selection of expression gene more critical. On the other hand, the expression host and purification process of Rubella virus-like particles also affect the activity of Rubella virus-like particles.
[0055] According to a specific embodiment of the present invention, those skilled in the art may replace, add and / or delete one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 or more) amino acids in the sequence of the present invention to obtain a variant of the sequence of the antibody or its functional fragment. They are all deemed to be included in the scope of protection of the present invention. For example, amino acids with similar properties are replaced in the variable region. The variant sequence of the present invention may have at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity (or homology) with the reference sequence. The sequence identity of the present invention can be measured using sequence analysis software, and the amino acid sequence of the recombinant virus-like particles of Rubella virus provided by the present invention is shown in SEQID NO.5.
[0056] SEQ ID NO.5:
[0057]
[0058]
[0059] According to a specific embodiment of the present invention, the recombinant virus-like particles of Rubella virus described in the present invention are empty shell structures that do not contain viral nucleic acids. The viral structural proteins (C, E1, E2) expressed by mammalian cells after specific transfection have the ability to automatically assemble into VLPs (virus like particles), which are similar to natural virus particles in morphology and structure, have strong immunogenicity and biological activity, and are not infectious because VLPs do not contain viral genetic material.
[0060] According to a specific embodiment of the present invention, the nucleotide sequence of the recombinant virus-like particle of Rubella virus provided by the present invention, or the nucleotide sequence of the recombinant plasmid provided by the present invention, can be used by those skilled in the art to prepare the same or similar virus-like particle protein (or its analogue) as that of the present invention by the method of expressing synthetic genes in heterologous cells (i.e., recombinant protein expression).
[0061] According to a specific embodiment of the present invention, the nucleotide sequence of the recombinant virus-like particle of Rubella virus provided by the present invention, or the nucleotide sequence of the recombinant plasmid provided by the present invention, due to the degeneracy of nucleic acid codons, those skilled in the art can adaptively change some bases to prepare the same or similar virus-like particle protein (or its analogue) as the present invention.
[0062] According to a specific embodiment of the present invention, the recombinant virus-like particles of the rubella virus of the present invention can be used to detect IgG and IgM antibodies that specifically recognize rubella virus in human serum or body fluids. The principle of detection is mainly based on the recognition and binding of the recombinant virus-like particles of the rubella virus of the present invention with IgG and IgM antibodies that specifically recognize rubella virus, and detection is performed using chemical labeling technology (such as labeled antibodies, or labeled specific secondary antibodies) or physical detection technology (such as light scattering technology, plasma resonance technology, etc.).
[0063] According to a specific embodiment of the present invention, the present invention provides a rubella vaccine, which can form rubella virus recombinant virus-like particles provided by the present invention in a recipient, and the vaccine has rubella virus immunogenicity, can induce an immune response of immune cells in the body, and store a certain amount of memory B cells. When the recipient injected with the vaccine is invaded by the rubella virus again, the stored memory B cells can respond quickly and produce more specific antibodies.
[0064] According to a specific embodiment of the present invention, the present invention mainly utilizes a genetic engineering method to prepare recombinant virus-like particles of rubella virus, and uses this as an antigen to prepare an enzyme immunoassay kit and a colloidal gold kit for detecting IgG and IgM antibodies that specifically recognize rubella virus in human serum. The detection results of IgG and IgM antibodies that specifically recognize rubella virus in human serum can be used as an auxiliary diagnosis of rubella virus infection.
[0065] According to a specific embodiment of the present invention, the present invention compares IgG and IgM antibodies in human serum detected by ELISA experiments using multiple inactivated natural rubella viruses, and selects the rubella virus substrain (Therien) with the best sensitivity and specificity as the expressed genotype. The coding sequence of the structural protein (C, E1, E2) of the Therien substrain is inserted into a mammalian cell expression vector to express rubella virus recombinant virus-like particles, wherein the inserted sequence is shown in SEQ ID NO.1.
[0066] SEQ ID NO.1:
[0067]
[0068]
[0069] According to a preferred embodiment of the present invention, the present invention optimizes and improves the transfection plasmid. The NEO resistance gene is replaced with the glutamine synthetase (Cricetulus GS) gene by the restriction enzyme sites SmaI and BstBI in the pCDNA3.1 plasmid, thereby reducing the later production cost. The nucleotide sequence of the GS gene is shown in SEQ ID NO.2. The optimized plasmid is named pCG3.1, and the full-length nucleotide sequence is shown in SEQ ID NO.3.
[0070] SEQ ID NO.2:
[0071]
[0072] SEQ ID NO.3:
[0073]
[0074]
[0075]
[0076] According to a specific embodiment of the present invention, the present invention uses ELISA experiments to detect the sensitivity and specificity of recombinant virus-like particles of Rubella virus expressed by different mammalian cells (M14, HeLa, HepG2, THP-1, MCF-7, CHO-S, 293S). After comparison, the performance of recombinant virus-like particles of Rubella virus expressed by CHO-S cells is the best among the other mammalian cells, but it does not mean that those skilled in the art cannot screen out cells with better performance than CHO-S cells in expressing recombinant virus-like particles of Rubella virus by similar methods.
[0077] According to a specific embodiment of the present invention, those skilled in the art can screen and obtain cells capable of expressing recombinant virus-like particles of Rubella virus by methods known in the art, including screening with methionine iminosulfone screening pressure.
[0078] According to a preferred embodiment of the present invention, the present invention gradually increases the final concentration of methionine iminosulfone to screen stable strains, shortens the screening period, and increases the cell unit yield of recombinant virus-like particles of rubella virus.
[0079] According to a specific embodiment of the present invention, those skilled in the art can purify recombinant Rubella virus virus-like particles by any method known in the art for purifying virus-like particles, including ultracentrifugation.
[0080] According to a preferred embodiment of the present invention, the present invention simplifies the purification process and increases the yield of recombinant virus-like particles of Rubella virus by pre-concentrating the cell supernatant by tangential flow and then purifying it by ultracentrifugation.
[0081] According to a specific embodiment of the present invention, those skilled in the art can culture the recombinant Rubella virus virus-like particles using any culture medium capable of culturing virus-like particles.
[0082] According to a specific embodiment of the present invention, the present invention compares the cell density and the yield of recombinant virus-like particles of rubella virus, and the preferred medium formula is: NaHCO 3 2.4 g; HEPES (1.5 M) 10.0 mL; selenic acid 10.0 mg; fibronectin 100 μg; insulin 1000.0 mg; transferrin 5000.0 mg; DMEM / F12 1:1 was mixed to dissolve the above solutes and the final volume was adjusted to 1000 mL.
[0083] According to a specific embodiment of the present invention, the labeling method of the recombinant virus-like particles of Rubella virus includes but is not limited to peroxidase (HRP) labeling. As a preferred technical solution of the present invention, the enzyme immunoassay kit prepared by using the recombinant virus-like particles of Rubella virus labeled with HRP is used.
[0084] The scheme of the present disclosure will be explained below in conjunction with the examples. Those skilled in the art will appreciate that the following examples are only used to illustrate the present disclosure and should not be considered to limit the scope of the present disclosure. Where specific techniques or conditions are not indicated in the examples, the techniques or conditions described in the literature in this area or the product instructions are used. Where the manufacturers of reagents or instruments are not indicated, they are all conventional products that can be obtained commercially.
[0085] Example 1 Identification of the ability of different subtypes of rubella virus to recognize specific IgG antibodies in human serum
[0086] Using the indirect ELISA method, CB buffer (Na 2 CO 3 1.59 g; NaHCO 3 2.94 g; 1L, pH 9.51) inactivated rubella viruses of different subtypes (BRDⅠ, BRDⅡ, Cendehill, M33, RN-UK86, Therien, TO-336, RA27 / 3) were diluted to 2 μg / ml, and 100 μl / well was coated in a 96-well ELISA plate at 4°C overnight. 2 PO 4 12H 2 O, 3.63 g; KCl, 0.2 g; KH 2 PO 4 , 0.24g; 1L, PH 7.4) and washed twice, 300μL / well. Then add blocking solution PTB (PBST, 1% BSA), 200μL / well, 37℃, block for 2 hours. Human serum samples were diluted 200 times with PTB and added to 96-well ELISA plates, 100μL / well, 37℃, 1 hour. Wash the plate 3 times with a plate washer, 300μL / well. After patting dry, add HRP-labeled mouse anti-human secondary antibody (Invitrogen, Cat#31420) diluted 10000 times with PTB, 100μL / well, 37℃, incubate for 1.5 hours. Wash the plate 3 times, 300μL / well. Add TMB color development solution (Pierce, Cat#34021) 100μL / well, room temperature, color development for 10 minutes. 1M HCl, 50 μL / well to terminate the reaction, and the OD 450 Read the value.
[0087] The experiment set up 3 human serum samples that were not infected with rubella virus (Negative1, Negative2, Negative13) and 5 human serum samples that were infected with rubella virus (Positive1, Positive2, Positive3, Positive4, Positive5). The data of 8 subtypes of rubella virus (BRDⅠ, BRDⅡ, Cendehill, M33, RN-UK86, Therien, TO-336, RA27 / 3) were compared to identify the specific IgG antibody ability in human serum. The results are as follows Figure 1 As shown, Therien has the highest specificity in recognizing IgG antibodies in human serum.
[0088] Example 2 Construction of pCG3.1 plasmid
[0089] First, refer to the GenBank nucleotide sequence X03495.1 (Chinese hamster mRNA for glutamine synthetase), the sequence is shown in SEQ ID NO.2. SmaI and BstBI restriction enzyme sites were inserted at the 5' and 3' ends respectively, and then the sequence was synthesized by a gene company. The synthesized gene and pCDNA3.1 (Thermo, catalog number: V79020) were double-digested with restriction endonucleases SmaI and BstBI respectively, and the gene fragments after gel recovery were connected by T4 ligase at 16°C overnight. The ligation product was transformed into TOP10 competent cells and the plasmid was extracted. The full-length nucleotide sequence of the obtained pCG3.1 plasmid is shown in SEQ ID NO.3, and the plasmid map is shown in Figure 2 .
[0090] Example 3 Construction of recombinant plasmid pCG3.1-Rubella (VLPs)
[0091] See SEQ ID NO.1 for the sequence. EcoRI and XbaI restriction enzyme sites were inserted at the 5' and 3' ends respectively, and the sequence was synthesized by a gene company. The synthesized gene and pCG3.1 were double-digested with restriction endonucleases EcoRI and XbaI respectively, and the gene fragments after gel recovery were connected by T4 ligase at 16°C overnight. The ligation product was transformed into TOP10 competent cells and the plasmid was extracted. The full-length nucleotide sequence of the obtained pCG3.1-Rubella (VLPs) plasmid is shown in SEQ ID NO.4, and the plasmid map is shown in Figure 3 .
[0092] SEQ ID NO.4:
[0093]
[0094]
[0095]
[0096] Example 4 Comparison of the activity of recombinant virus-like particles of Rubella virus transiently expressed in different mammalian cells
[0097] (1) Cell transfection
[0098] The pCG3.1-Rubella (VLPs) plasmid was extracted with DNA extraction phenol reagent (Solebol, Cat#T0250). 25 μg of the extracted plasmid was mixed with 25 μL Lipofectamine TM3000 transfection reagent (Invitrogen, Cat#L3000015) was premixed for 10 minutes and then mammalian cells (M14, HeLa, HepG2, THP-1, MCF-7, CHO-S, 293S) were transfected. The adherent cells transfected were M14, HeLa, HepG2, THP-1, MCF-7, and the suspension cells transfected were CHO-S and 293S. The cell culture volume was 30 ml and the cell density was 1×10 6 / ml. Place at 37℃, 5% CO 2 The cells were placed in a culture box or cultured at 130 rpm. After 48 hours of culture, the supernatant of each cell culture was centrifuged at 200 × g for 10 minutes to collect the supernatant.
[0099] (2) ELISA sandwich assay for the activity of Rubella virus-like particles (VLPs)
[0100] Sheep anti-Rubella virus polyclonal antibody (Virostat, Cat#1701) was diluted to 1μg / mL with CB buffer, and 100μL / well was coated in a 96-well ELISA plate at 4°C overnight. The plate was washed twice with PBST, 300μL / well. Then the blocking solution PTB was added, and the plate was blocked at 37°C for 2 hours. The supernatants of the above transfected cells were added to a 96-well ELISA plate, 100μL / well, 37°C, for 1 hour. The plate was washed 3 times with a plate washer, 300μL / well. After patting dry, HRP-labeled sheep anti-Rubella virus polyclonal antibody (Virostat, Cat#1701) diluted 500 times with PTB was added, 100μL / well, 37°C, and incubated for 1 hour. The plate was washed 3 times, 300μL / well. Add TMB color development solution for 10 minutes. 1MHCl, 50uL / well to terminate the reaction, and use an enzyme reader OD 450 The data were used to compare the activity of recombinant virus-like particles of rubella virus transiently expressed in different mammalian cells (M14, HeLa, HepG2, THP-1, MCF-7, CHO-S, 293S). The results are shown in Figure 4 , indicating that compared with other cell types, CHO-S cells have higher activity in transiently expressing rubella virus recombinant virus-like particles.
[0101] Example 5 Screening of CHO-S Stable Cell Lines Expressing Rubella (VLPs)
[0102] After 2-3 passages, the CHO-S cells were revived and the cell concentration was 1.3×10 6After shaking the flask, use a sterile pipette (Corning, #4488) to draw 23 mL of cell solution and add it to a new 125 mL shake flask, and fill it up to 30 mL with CD-CHO medium (Thermo, catalog number: 10743029). Ensure that the cell concentration is 1×10 6 cells / mL, and temporarily place the shake flask in an incubator. Dissolve 37.5μg of plasmid pCG3.1-Rubella (VLPs) in 0.6mL of SFM medium and mix gently. Dissolve 37.5μL of free style MAX in 562.5μL of SFM medium to a total volume of about 0.6mL (incubate for 5 minutes, with precise timing). Mix the DNA with the MAX solution and react at room temperature for 25 minutes. Add all of the reaction mixture (slowly) to the CHO-S cells as described above. Place the shake flask in a CO 2 Incubator (37°C, 5% CO 2 ) in a shaking incubator (130 rpm) for 48 h.
[0103] After transfection and culturing for 48 hours, the cells were plated in 96-well cell culture plates using CDCHO medium (Gibco, Cat#10743029). Different concentrations of methioninesulfoximine (MSX) were added to the medium, with concentrations of 0, 6.25, 12.5, 25, 50, and 100 μM. Different cell densities were plated at each MSX concentration, with cell densities of 10 cells / well, 100 cells / well, and 1000 cells / well, respectively. Five plates were plated for each condition. The cells were incubated at 37°C and 5% CO 2 The cells were cultured in an incubator. After 20-30 days, when the cell clusters reached about 500 cells, the cell supernatant was collected and the expression of Rubella (VLPs) in the supernatant was detected by double antibody sandwich ELISA.
[0104] First, sheep anti-rubella virus polyclonal antibody (Virostat, Cat#1701) was diluted to 1 μg / mL with CB buffer, and 100 μL / well was coated in a 96-well ELISA plate at 4°C overnight. The plate was washed twice with PBST, 300 μL / well. Then, blocking solution PTB was added, and the plate was blocked at 37°C for 2 hours. The supernatants of the above transfected cells were added to a 96-well ELISA plate, 100 μL / well, 37°C, for 1 hour. The plate was washed 3 times with a plate washer, 300 μL / well. After patting dry, HRP-labeled sheep anti-rubella virus polyclonal antibody diluted 500 times with PTB was added, 100 μL / well, 37°C, and incubated for 1 hour. The plate was washed 3 times, 300 μL / well. TMB color development solution was added for 10 minutes. 1M HCl, 50 ul / well was used to terminate the reaction, and the absorbance (A450) was measured at 450 nm using an ELISA reader. The OD value of the negative control was 2.1 times or more, which was considered positive (calculated after adjusting the blank control well to zero). The cells in the positive wells were selected to maintain the MSX concentration, and the screening was repeated once according to the above method. The cells in the positive wells were transferred to a 24-well plate for expansion and culture. Each clone should be frozen as soon as possible, and the cell line with clone number 180H2 was finally selected for Rubella (VLPs) production.
[0105] Example 6 Mass preparation of Rubella (VLPs) and activity determination
[0106] (1) Large-scale preparation of Rubella (VLPs)
[0107] The stable cell line of clone 180H2 was thawed in a 37°C water bath within 1-2 minutes. 9 mL of CD-CHO medium was added to a 15 mL centrifuge tube, followed by the thawed cell suspension. After centrifugation at 200 × g for 5 minutes, the cells were transferred to a 125 mL shake flask, 12.5 μM MSX was added, and the volume was adjusted to 30 mL. The tube was placed in a CO 2 Incubator (37°C, 5% CO 2 ) in a shaker (130 rpm) for 2 days. The culture volume was then gradually increased to maintain the initial cell density at 0.2-0.5×10 6 / mL until the culture volume is expanded to 5L, and the cell density is tested every day. The results are shown in Figure 5 When the culture time is before 7 days, the cell density increases rapidly, and after 7 days, the cell density decreases slowly. At the same time, the cell viability is tested every day. The results are shown in Figure 6 After the cell density reached its peak, the cell viability began to show a significant downward trend until the cell viability was lower than 80% (about 13 days of cell culture), and the cell supernatant (volume of about 5 L) was collected by centrifugation at 200×g.
[0108] The collected cell supernatant was filtered using a tangential flow system (Sartorius, viva flow 200PES-100K, effective filtration area 0.02 m 2 ), the specific method is as follows: Use 1L of pure water (0.22uM filtration) to clean the TFF membrane system, and the peristaltic pump speed is 100rpm. The filtrate flow rate is 100mL / min. Place the injection tube and reflux tube of the membrane package into a PP beaker containing cell supernatant, pump speed 150rpm, injection pressure 1.2bar, initial flow rate 30mL / min, and final flow rate 20mL / min. Until the solution is concentrated to 500ml (i.e. 5L is concentrated to 500ml, concentrated 10 times). Collect the concentrate and filtrate and store at 4℃. Continue to perform discontinuous density gradient centrifugation with 10%, 20%, 40%, and 60% sucrose (100000×g, centrifugation for 1 hour), harvest the Rubella (VLPs) band and dialyze and concentrate to 5ml. Finally, the concentrated Rubella (VLPs) solution 1mL / tube is divided into centrifuge tubes and stored at -80℃. The antibody concentration was determined using a BCA kit (Solabo, PC0020), and the total concentration of purified Rubella (VLPs) was 7.2 mg / mL.
[0109] (2) Activity assay of Rubella (VLPs)
[0110] Double antibody sandwich ELISA was used to detect the activity of Rubella (VLPs) in the supernatant. Rubella (VLPs) and sheep anti-rubella virus polyclonal antibody (Virostat, Cat#1701) were diluted to 1 μg / mL with CB buffer, and 100 μL / well were coated in a 96-well ELISA plate at 4°C overnight. The plate was washed twice with PBST, 300 μL / well. Then the blocking solution PTB was added, and the plate was blocked at 37°C for 2 hours. Rubella (VLPs) and RubelaVirus K1SAntigen (Microbix, Cat#EL-05-10, naturally inactivated virus) were diluted with PTB to different concentrations and added to a 96-well ELISA plate, 100 μL / well, 37°C, for 1 hour. The plate was washed 3 times with a plate washer, 300 μL / well. After patting dry, HRP-labeled sheep anti-rubella virus polyclonal antibody diluted 500 times with PTB was added, 100 μL / well, and incubated at 37°C for 1 hour. Wash the plate 3 times, 300 μL / well. Add TMB colorimetric solution for 10 minutes. 1M HCl, 50 μL / well to terminate the reaction, and use an ELISA reader to measure the absorbance (A450) at 450 nm. The results are shown in Table 1, indicating that the recombinant protein particles VLPs expressed by the recombinant plasmid provided by the present invention have similar activities to those of natural inactivated viruses.
[0111] Table 1
[0112]
[0113] Example 7 Optimization of serum-free medium for the production of 180H2 cell line Rubella (VLPs)
[0114] In order to achieve the best protein expression level and reduce production costs, a serum-free medium for the production of 180H2 cell line Rubella (VLPs) is needed. After mixing DMEM / F12 1:1, different concentrations of NaHCO 3 (1.2, 2.4, 3.6 g / L); HEPES (15mM, 30mM, 45mM); selenoic acid (50, 75, 100 μg / L); fibronectin (100, 150, 200 μg / L); insulin (1, 1.5, 2 g / L); transferrin (2.5, 3.5, 5 g / L). After 0.22 μM filtration and sterilization, 30 mL of the above culture medium was used to culture the 180H2 cell line in a 125 mL shake flask, and CDCHO medium was used as a control. The cells were counted every day, and the cell density of different culture days was compared. Through comparison, the optimized culture medium formula finally screened out is as follows: NaHCO 3 2.4g; HEPES (1.5M) 10.0ml; selenic acid 10.0mg; fibronectin 100μg; insulin 1000.0mg; transferrin 5000.0mg; DMEM / F12 1:1 mixed and dissolved the above solutes, and the final volume was 1000mL. The growth curves of 180H2 cells cultured in the optimized culture medium and CDCHO culture medium were compared. The results are shown in Figure 7 As shown in the figure, the peak cell density of 180H2 cell line in the optimized culture medium is higher than that in CDCHO culture medium, the peak cell density is reached earlier than that in CDCHO culture medium, and the cell density change rate in the later period of the peak density is also lower than that in CDCHO culture medium. It can be seen that the optimized culture medium is more suitable for the culture of 180H2 cell line than CDCHO culture medium.
[0115] Example 8 Identification of the sensitivity and specificity of Rubella (VLPs) in detecting specific IgG and IgM antibodies in serum
[0116] The ability of Rubella (VLPs) to detect the sensitivity of specific IgG and IgM antibodies in serum was evaluated by indirect ELISA. In this experiment, Rubella (VLPs), Rubella E1 (E1, prokaryotic expression of Rubella virus E1 recombinant protein) and RubelaVirus K1SAntigen (Microbix, Cat# EL-05-10, naturally inactivated virus) were diluted with CB buffer as antigens and coated in 96-well ELISA plates at a coating concentration of 1μg / mL and a volume of 100μL / well. After overnight coating at 4°C, the ELISA plates were washed twice with PBST solution, 300μL / well each time. After washing, pat dry, and the ELISA plates were blocked with PBS solution containing 1% BSA, 200μL / well, at room temperature for 2 hours. Pat dry, serum samples were diluted 100 times with PTB, and then added to the above blocked ELISA plates, 100μL / well, and reacted in a 37°C incubator for 1 hour. Pat dry, wash the plate 3 times with PBST, 300 μL / well each time. Pat dry, add HRP-labeled mouse anti-human IgG antibody (Thermo, Cat. No.: 31430) or IgM antibody (Thermo, Cat. No.: 62-6820) diluted 5000 times with PTB to the ELISA plate, and react in a 37°C incubator for 1 hour. Wash the plate 3 times with PBST, 300 μL / well. Pat dry, add TMB substrate solution to the ELISA plate, 100 μL / well, incubate at room temperature for 10 minutes, and then add 100 μL / well of 1M H 2 SO 4 , terminate the reaction. Use an enzyme-labeled instrument to measure the absorbance (A450) at 450nm. The experimental results are as follows Figure 8 As shown, it can be seen that the sensitivity and specificity of Rubella (VLPs) in detecting specific IgG and IgM antibodies in serum are better than Rubella E1 and RubelaVirus K1SAntigen.
[0117] Example 9 Application of ELISA kit prepared using Rubella (VLPs) in detecting rubella virus antibodies in human serum
[0118] (1) Horseradish peroxidase (HRP) labeling of Rubella (VLPs) antigens and identification of labeled products
[0119] Take 0.5mL R Rubella (VLPs) antigen (2mg) and add it to a dialysis bag (10KDa, width 1cm), and dialyze it in 2L 10mM PBS solution (PH 7.4) at 4°C overnight. The next day, put the dialysis bag containing the antibody solution into 1L 10mM carbonate buffer (PH 9.5) and dialyze it at room temperature for 2 hours, ready for coupling with activated HRP.
[0120] At the same time, accurately weigh 1 mg of HRP using an analytical balance and add 0.2 mL of ultrapure water to dissolve it so that the HRP concentration is 5 mg / mL. Add 40 μl of 0.1 M NaIO 4 , placed on a horizontal shaker, react (activate) at room temperature in the dark for 20 minutes. Add the activated HRP solution to a dialysis bag (10KDa, 1cm width) and dialyze in 2L 1mM sodium acetate buffer (PH4.4) at 4°C overnight. Carefully aspirate the dialyzed HRP solution and transfer it to a new 1.5mL centrifuge tube, add 1 / 10 volume of 0.2M carbonate buffer to raise the pH of the activated HRP solution to 9.0-9.5.
[0121] Mix the above antibody and HRP (for coupling reaction), place on a horizontal shaker, and react at room temperature in the dark for 4 hours. After the coupling reaction is completed, add 10 μL (pre-cooled ultrapure water) of freshly prepared NaBH 4 , and stop the reaction at 4°C in the dark overnight. After the coupling reaction is terminated, transfer the antibody solution to a dialysis bag (10KDa, width 1cm) and dialyze for 2 hours at room temperature. Finally, transfer the solution to a brown centrifuge tube and store at 4°C.
[0122] The optimal dilution of HRP-labeled Rubella (VLPs) antigen for detecting rubella virus antibodies was evaluated by capture ELISA. In the experiment, mouse anti-human IgM was diluted to 1 μg / mL with CB buffer, and then 100 μL / well was coated in a 96-well ELISA plate (overnight at 4°C). The plate was washed twice with 300 μL / well PBST. Pat dry, block the ELISA plate with PBS solution containing 1% BSA, 200 μL / well, at room temperature for 2 hours. Pat dry, add human rubella virus IgM positive serum diluted 100 times with PTB, and react in a 37°C incubator for 1 hour. Wash the plate 3 times with PBST, 300 μL / well each time. Pat dry, add HRP-labeled Rubella (VLPs) antigen (diluted with PTB) solution with different dilution ratios, 100 μL / well, and react in a 37°C incubator for 1 hour. Wash the plate 3 times with PBST, 300 μL / well each time. Pat dry, add TMB substrate solution, 100 μL / well, react at room temperature for 10 minutes. Then add 100 μL / well 1M H 2 SO 4 The reaction was terminated. The absorbance (A450) was measured at 450 nm using an ELISA reader. As shown in Table 2, the optimal dilution of the labeled Rubella (VLPs) antigen was 400 times.
[0123] Table 2
[0124] Dilution factor of HRP labeled VLPs OD450 50 0.786 100 1.052 200 1.242 400 1.255 800 0.963 1600 0.835 3200 0.435 6400 0.214 Background 0.089
[0125] (2) ELISA kit prepared using Rubella (VLPs) antigen for the detection of rubella virus antibodies in human serum
[0126] Mouse anti-human IgM was diluted to 1 μg / mL with CB buffer, and then 100 μL / well was coated in a 96-well ELISA plate (overnight at 4°C). The plate was washed twice with 300 μL / well PBST. Pat dry, block the ELISA plate with PBS solution containing 1% BSA, 200 μL / well, at room temperature for 2 hours. Pat dry, add human rubella virus IgM positive serum diluted 100 times with PTB, and react in a 37°C incubator for 1 hour. Wash the plate 3 times with PBST, 300 μL / well each time. Pat dry, add 400-fold diluted HRP-labeled Rubella (VLPs) antigen (diluted with PTB) solution, 100 μL / well, and react in a 37°C incubator for 1 hour. Wash the plate 3 times with PBST, 300 μL / well each time. Pat dry, add TMB substrate solution, 100 μL / well, and react at room temperature for 10 minutes. Then add 100 μL / well of 1M H 2 SO 4 The reaction was terminated. The absorbance (A450) was measured at 450 nm using an ELISA instrument. A value 2.1 times or more of the negative control OD value was considered positive (calculated after zeroing the blank control well). The results are shown in Table 3, which show that the enzyme-immune test kit prepared using the Rubella (VLPs) antigen of the present invention is used for the detection of rubella virus antibodies in human serum, and the detection accuracy is high.
[0127] Table 3
[0128] sample Negative sample 1 Negative sample 2 Negative sample 3 Positive sample 1 Positive sample 2 Positive sample 3 OD450 0.132 0.098 0.115 1.532 1.241 0.996 Positive and negative determination Negative Negative Negative Positive Positive Positive
[0129] The rubella virus recombinant protein expressed by the rubella virus recombinant virus-like particle expression vector provided by the present invention covers all structural proteins (C, E1, E2) of rubella virus, and the expressed recombinant protein exists in the form of virus-like particles. The preparation process is simple, the antigen purity is high, and the detection sensitivity and specificity are better than those of inactivated natural rubella virus and recombinantly expressed rubella virus single or multiple combination protein fragments, which can effectively avoid the above problems and provide more specific and accurate raw materials for the detection of rubella virus infection.
[0130] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "example", "specific example", "some implementation schemes" or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine the different embodiments or examples described in this specification and the features of the different embodiments or examples, unless they are contradictory.
[0131] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.
Claims
1. Rubella virus recombinant virus-like particles, It is characterized in that Obtained through CHO-S cell expression, in, The CHO-S cells are recombinant cells containing an expression vector. The starting plasmid of the expression vector is pCDNA3.1, wherein the neomycin resistance gene on the pCDNA3.1 is replaced by the glutamine synthetase gene, and the nucleotide sequence of the expression vector is shown in SEQ ID NO.4, which includes nucleotides encoding the capsid protein and envelope protein of the Therien subtype rubella virus, wherein the capsid protein is protein C, and the envelope protein is protein E1 and protein E2; The diameter of the recombinant Rubella virus-like particles is 100-150 nm.
2. The recombinant Rubella virus-like particle according to claim 1, It is characterized in that The recombinant rubella virus-like particles do not contain genetic material of rubella virus.
3. A kit, It is characterized in that Comprising the rubella virus recombinant virus-like particles according to claim 1 or 2.
4. Use of the recombinant Rubella virus-like particles according to claim 1 or 2 in preparing a kit, It is characterized in that The kit is used for detecting rubella virus.
5. The use according to claim 4, It is characterized in that The kit is an enzyme immunoassay kit, a colloidal gold detection kit or a chemiluminescence detection kit.
6. A composition, It is characterized in that Comprising the rubella virus recombinant virus-like particles according to claim 1 or 2.
